Insider Cluster (3 insiders) ·Filed Jul 2, 2026

RPRX

Royalty Pharma plc
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago
Insider cluster: 2 insiders, $6.0M total
Actionable Insight • Neutral

The selling is too small to be informative. Monitor for any larger insider activity or a follow-up 8-K with material corporate news. For now, this cluster has no actionable trade signal.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
RPRX ▲ +1.04% at T+60d
NEUTRAL call ✓ call won +1.04% · α vs SPY -2.53% · entry $57.77 → $58.37
Entry anchored
Jul 2, 03:59 PM ET
via exchange tick
T+1d
-1.47%
call -1.47% · α -2.34%
$56.92
settled 3mo ago
T+5d
+0.33%
call +0.33% · α -0.60%
$57.96
settled 3mo ago
T+20d
+2.16%
call +2.16% · α +2.58%
$59.02
settled 2mo ago
T+60d
+1.04%
call +1.04% · α -2.53%
$58.37
settled 4d ago

Price Chart

Loading chart...

Executive Summary

Two EVP-level insiders at Royalty Pharma (RPRX) sold a combined $7.85M in shares over a 7-day window, but this represents only ~0.024% of the company's $32.1B market cap. The selling is trivial in size relative to the company's valuation and is unlikely to carry a material signal.

Key Financial Metrics

Direction
selling
Total Value
$7.9M
Insiders
3

Key Facts

  • EVP & Chairman, Partnering Christopher Hite sold $7.35M across four open-market trades at $56.44–$57.10.
  • EVP, Research & Investments Marshall Urist sold $508K at $55.88.
  • Director Bonnie Bassler received a non-cash grant of 689 shares worth $37.5K.
  • Total insider cash sales of $7.85M are just 0.024% of RPRX's $32.1B market cap.
  • No 10b5-1 plan indication; the sales may be routine diversification.

Financial Impact

Insider sales of $7.85M are negligible relative to a $32.1B market cap (0.024%). No material financial impact.

Risk Factors

  • Insider sales could accelerate if the stock appreciates further, but current levels are not alarming.
  • No correlation with upcoming earnings or corporate events based on available data.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RPRX-1783062576498
18 reports for RPRX
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +15.20%May 6, 2026
Filters
Rows
Reports for RPRX — sortable, filterable
TypeNow
Sep 4, 2026
27d ago
Press Release
BEARISH ★ 5/10
$60.59 $58.47▲ +3.50%▲ +2.38%$57.16 (+5.66%)
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 3/10
$61.73 $61.80▲ +0.11%▲ +0.50%$57.16 (−7.40%)
Aug 12, 2026
7w ago
144
NEUTRAL ★ 3/10
$58.56 $60.58▲ +3.45%▲ +5.41%$57.16 (−2.39%)
Aug 5, 2026
8w ago
8-K
BULLISH ★ 6/10
$57.75 $59.22▲ +2.55%▲ +2.19%$57.16 (−1.02%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$57.77 $57.96▲ +0.33%▼ −0.60%$57.16 (−1.06%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$57.77 $57.96▲ +0.33%▼ −0.60%$57.16 (−1.06%)
May 28, 2026
18w ago
Insider Cluster
NEUTRAL ★ 4/10
$55.76 $55.87▲ +0.20%▲ +2.72%$57.16 (+2.51%)
May 28, 2026
18w ago
8-K
NEUTRAL ★ 4/10
$55.76 $54.97▼ −1.42%▼ −1.12%$57.16 (+2.51%)
May 22, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$54.50 $55.18▲ +1.25%▼ −0.41%$57.16 (+4.88%)
May 15, 2026
19w ago
Insider Cluster
NEUTRAL ★ 3/10
$52.07 $53.86▲ +3.44%▲ +1.82%$57.16 (+9.78%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (65h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 3, 2026